New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePal-AHK vs PT-141 (Bremelanotide)

Pal-AHK vs PT-141 (Bremelanotide)

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Pal-AHK
Sexual Health & Libido
PT-141 (Bremelanotide)
Summary
Pal-AHK is the palmitoylated form of the AHK-Cu copper tripeptide, created by attaching a palmitic acid chain to enhance skin penetration and lipid bilayer affinity. The palmitoyl modification significantly improves dermal bioavailability compared to unmodified AHK, making it particularly effective in anti-aging and hair growth formulations.
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Half-Life
Extended (lipid depot effect in stratum corneum)
2–3 hours
Admin Route
Topical
SubQ
Research
Typical Dose
0.01–0.05% in formulation
0.5–1.75 mg
Frequency
Once or twice daily
As needed (not daily)
Key Benefits
  • Enhanced skin penetration vs. unmodified AHK-Cu
  • Stimulates dermal collagen and elastin production
  • Promotes hair follicle anagen phase
  • Antioxidant and wound healing activity
  • Firming and plumping effect on aging skin
  • Improved bioavailability via lipid bilayer incorporation
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
Side Effects
  • Generally well-tolerated
  • Mild irritation at high concentrations in sensitive skin
  • Possible comedogenicity at very high palmitate concentrations (formulation-dependent)
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
Stacks With